All In Biotech

Drug Trial Radar · NCT07373262

Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement

Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement: a Randomized, Placebo-controlled, Double-blinded Multicenter Superiority Study

Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Mar 1, 2030

Study completion Jul 1, 2030

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ANCA-associated vasculitis (AAV) is a rare auto-immune disease, with high mortality in the absence of treatment. There is still an unmet need to define new treatment strategies to reduce drug side effects, as well as to reverse rare cases of refractory AAV and improve the kidney response to improve the long-term outcomes. Severe forms of AAV-related necrotizing and crescentic rapidly progressive glomerulonephritis (RPGN) (i.e. estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²) are associated with higher mortality, higher incidence of infections, and long-term consequences including chronic kidney disease (CKD) with subsequent complications (end-stage kidney disease (ESKD) requiring dialysis, cardiovascular diseases) and a burden of financial costs. In patients with AAV and RPGN, recent guidelines recommend using a standard-of-care (SOC) immunosuppressive regimen including an induction regimen (rituximab or cyclophosphamide), plus glucocorticoids (GCs) (starting at 60 mg/day and tapering over 6-12 months) (+ or - plasma exchanges). Since GCs also participate to the long-term control of AAV, new molecular pathophysiology-driven therapeutic approaches rapidly blocking and/or reversing AAV lesions are needed to go beyond the progressive control of AAV using GCs alone. Thus, an add-on approach including GCs-based immunosuppressive regimen plus a new targeted therapy may lead to both AAV control (systemic disease) and improvement of the kidney outcome (organ involvement). Avacopan a selective inhibitor of the C5a receptor, recently emerged as a new therapeutic option in AAV. In a phase 3 comparative study (that included a small subset of patients with eGFR 15-29 mL/min/1.7m2), avacopan was superior to glucocorticoids taper with respect to sustained remission at week 52. In the avacopan arm, the cumulative dose of GCs was dramatically reduced and avacopan was thus proposed as an alternative to GCs rather to a synergic treatment. In the subgroup of patients with eGFR \<30 mL/min/1.73m², avacopan was associated with a better eGFR gain at week 52 compared to prednisone, but data in this population at-risk of worse kidney outcomes are scarce, and did not include patients with eGFR \< 15 mL/min/1.73m², those patients being excluded from the study. In the REVERSE study, investigators put forward the hypothesis that avacopan added on GCs regimen may significantly improve the kidney outcome of severe AAV (synergic approach), and thus improve short- and long-term global outcomes (survival, cardiovascular status). REVERSE will thus compare GCs-based SOC + placebo to GCs-based SOC + avacopan.

Conditions

  • ANCA-Associated Vasculitis (AAV)

Interventions

  • AvacopanDrug

    At day 0, and weeks 4, 8, 12, 20 36 patients will have avacopan dispensation

  • PlaceboDrug

    At day 0, and weeks 4, 8, 12, 20 36 patients will have placebo dispensation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in the kidney functionTime frame: Day 0 and 52 weeks after randomization

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Amiens Hospital

    Amiens, France

  • Angers Hospital

    Angers, France

  • Besançon Hospital

    Besançon, France

  • Bordeaux Hospital

    Bordeaux, France

  • Boulogne-sur-Mer Hospital

    Boulogne-sur-Mer, France

  • Brest Hospital

    Brest, France

  • Caen Hospital

    Caen, France

  • Grenoble Hospital

    Grenoble, France

  • Vendée Hospital

    La Roche-sur-Yon, France

  • Le Mans Hospital

    Le Mans, France

  • Lille Hospital

    Lille, France

  • Limoges Hospital

    Limoges, France

  • Marseille Hospital

    Marseille, France

  • Nantes Hospital

    Nantes, France

  • Nimes Hospital

    Nîmes, France

  • Bichat Hospital

    Paris, France

  • Cochin Hospital

    Paris, France

  • George Pompidou Hospital

    Paris, France

  • Henri Mondor Hospital

    Paris, France

  • Kremlin Bicêtre Hospital

    Paris, France

  • Necker Hospital

    Paris, France

  • Tenon Hospital

    Paris, France

  • Reims Hospital

    Reims, France

  • ROuen Hospital

    Rouen, France

  • Strasbourg Hospital

    Strasbourg, France

  • Saint exupery hospital

    Toulouse, France

  • Toulouse Hospital

    Toulouse, France

  • Tours Hospital

    Tours, France

  • Valenciennes Hospital

    Valenciennes, France

  • NANCY Hospital

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.